Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Investment Securities (2016 - 2025)

Iovance Biotherapeutics has reported Gains from Investment Securities over the past 7 years, most recently at -$6.7 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$6.7 million for Q4 2025, up 31.16% from a year ago — trailing twelve months through Dec 2025 was -$14.2 million (down 92.45% YoY), and the annual figure for FY2025 was $18.9 million, up 3.72%.
  • Gains from Investment Securities for Q4 2025 was -$6.7 million at Iovance Biotherapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for IOVA hit a ceiling of $19.0 million in Q2 2025 and a floor of -$9.7 million in Q4 2024.
  • Median Gains from Investment Securities over the past 3 years was $2.4 million (2023), compared with a mean of $4.6 million.
  • Peak annual rise in Gains from Investment Securities hit 7232.08% in 2024, while the deepest fall reached 272.14% in 2024.
  • Iovance Biotherapeutics' Gains from Investment Securities stood at -$2.6 million in 2023, then crashed by 272.14% to -$9.7 million in 2024, then soared by 31.16% to -$6.7 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$6.7 million (Q4 2025), $2.8 million (Q3 2025), and $19.0 million (Q2 2025) per Business Quant data.